Cargando…
Low-Dose TMP-SMX in the Treatment of Pneumocystis jirovecii Pneumonia: A Systematic Review and Meta-analysis
BACKGROUND: Pneumocystis jirovecii pneumonia (PJP) remains a common and highly morbid infection for immunocompromised patients. Trimethoprim-sulfamethoxazole (TMP-SMX) is the antimicrobial treatment of choice. However, treatment with TMP-SMX can lead to significant dose-dependent renal and hematolog...
Autores principales: | Butler-Laporte, Guillaume, Smyth, Elizabeth, Amar-Zifkin, Alexandre, Cheng, Matthew P, McDonald, Emily G, Lee, Todd C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7200085/ https://www.ncbi.nlm.nih.gov/pubmed/32391402 http://dx.doi.org/10.1093/ofid/ofaa112 |
Ejemplares similares
-
Low-dose trimethoprim-sulfamethoxazole for the treatment of Pneumocystis jirovecii pneumonia (LOW-TMP): protocol for a phase III randomised, placebo-controlled, dose-comparison trial
por: Sohani, Zahra N., et al.
Publicado: (2022) -
On the Treatment of Pneumocystis jirovecii Pneumonia: Current Practice Based on Outdated Evidence
por: McDonald, Emily G, et al.
Publicado: (2021) -
1304. Antimicrobial Management of Stenotrophomonas maltophilia Pneumonia: Does TMP-SMX Dose Affect Treatment Failure?
por: Keck, J Myles, et al.
Publicado: (2021) -
Use of Oropharyngeal Washes to Diagnose and Genotype Pneumocystis jirovecii
por: Juliano, Jonathan J., et al.
Publicado: (2015) -
Treatment With Reduced-Dose Trimethoprim-Sulfamethoxazole Is Effective in Mild to Moderate Pneumocystis jirovecii Pneumonia in Patients With Hematologic Malignancies
por: Hammarström, Helena, et al.
Publicado: (2022)